Cambridge Cognition the neuroscience company which develops and markets near patient technologies for the assessment of brain health has secured two further major contracts for the Company’s CANTAB Connect technology. This is the latest and most deployable and flexible version of the CANTAB platform which has 30 years of academic and clinical validation behind it. The contracts, for late stage clinical trials for US biopharmaceuticals companies, total £2.82m (US$3.67m); of which &
30 Sep 2016
CANTAB Connects with US Biopharmaceutical Firms
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CANTAB Connects with US Biopharmaceutical Firms
Cambridge Cognition Holdings Plc (COG:LON) | 52.0 0 0.0% | Mkt Cap: 18.3m
- Published:
30 Sep 2016 -
Author:
Derren Nathan -
Pages:
6
Cambridge Cognition the neuroscience company which develops and markets near patient technologies for the assessment of brain health has secured two further major contracts for the Company’s CANTAB Connect technology. This is the latest and most deployable and flexible version of the CANTAB platform which has 30 years of academic and clinical validation behind it. The contracts, for late stage clinical trials for US biopharmaceuticals companies, total £2.82m (US$3.67m); of which &